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Abstract
Patients with cancer often develop major electrolyte disorders, which are aggravated by radiation therapy and chemotherapy and by the
concomitant impairment of the renal function and the development of drug resistance. In addition, tumour cells have membranes with more
negative charges than normal eukaryotic cells. This study was designed to test the hypothesis that the ability of the Ca2 + blocker verapamil to
mediate the reversal of multidrug resistance (MDR) by interacting with the membrane phospholipids may be correlated with the ionic
strength and membrane surface potential in resistant tumours. The permeation properties of verapamil, which is the best-known MDR-
modulator, were therefore studied by quantifying its ability to induce the leakage of carboxyfluorescein through unilamellar liposomes
containing various mole fractions of phosphatidic acid (xEPA= 0, 0.1 and 0.3), at four different ionic strengths (I = 0.052, 0.124, 0.204 and
0.318 M). The dye leakage induced by verapamil varied greatly with I, depending on xEPA. The permeation process was a co-operative one
(1.3 <Hill coefficient < 3.5) and the permeation doses inducing 50% dye leakage (PD50) ranged between 0.2 and 1.8 mM. A highly
significant multiple correlation was found to exist between the variations of log(1/PD50) with those of 1/MI and xEPA (dlog(1/PD50)/d(1/
MI) = 0.15F 0.01, dlog(1/PD50)/dxEPA= 2.07F 0.08, y-intercept = 2.46F 0.03, P< 0.000001). Kinetic studies on the permeation process
showed that it involved two steps. The apparent rate constants of the slow and fast kinetic steps, which were driven by electrostatic and
hydrophobic interactions, respectively, increased with the verapamil concentrations, depending on xEPA. The results provide evidence that in
resistant tumours (high negative membrane surface potential), the MDR reversal by verapamil might be enhanced by favourable drug–
membrane interactions in patients with severe hypo-electrolytic (Na+ and K+) disorders, whereas the MDR reversal might be reduced by
unfavourable drug–membrane interactions in patients with severe hyper-electrolytic (Ca2 +, Na+ and K+) disorders.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Patients with cancer may develop major electrolyte
disturbances due to local disorders caused by the tumour,
substances produced by the tumour and surgical defects
resulting from resection of the cancer. Radiation therapy and
chemotherapy are additional stresses which may induce
fluid and electrolyte problems that are seldom simple [1–
5]. Benign and malignant neoplasms may also affect the
renal function by: (i) anatomically involving the kidneys,
ureters or bladder; (ii) secreting hormones that secondarily
affect the renal function; (iii) destroying bone and endocrine
organs, thus secondarily causing renal electrolyte abnormal-
ities; (iv) responding to specific therapy that may produce
renal electrolyte disorders [6]. In the advanced stages of the
disease, the patient is debilitated, more susceptible to acid–
base balance problems and fluid or electrolyte disorders and
less capable of adjusting to or compensating for such
disorders. Carcinoma is a complex problem requiring com-
plex and often multiple curative or palliative efforts, espe-
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cially in those cases where clinical resistance to chemo-
therapeutic drugs develops during the therapy.
When treated with chemotherapeutic drugs many cancer
cells take advantage of their ability to develop a resistance
phenotype, as part of an adaptive mechanism. The multidrug
resistance (MDR) is characterized by cross-resistance of the
cells towards a broad range of structurally and functionally
unrelated drugs after cell exposure to a single drug [7]. The
MDR process is generally associated with the overexpres-
sion of a cell-surface P-glycoprotein (P-gp). This protein acts
as an energy-dependent efflux pump, extruding cytotoxic
agents from tumour cells, thus abolishing their cytotoxic
effects [7]. Since the first report on the pharmacological
reversal of MDR by the Ca2 + blocker verapamil [8], a
variety of substance (modulators, chemosensitizers) have
been found to inhibit P-gp-mediated drug efflux and thus
to reverse MDR to chemotherapeutic agents. Among the
mechanisms suggested to explain their anti-MDR action
[7, 9–12], it has been speculated that drug–membrane inter-
actions between the MDR-modulators and the membrane
phospholipids may play a role in the MDR reversal [11].
Because most of the MDR-modulators are highly lipophilic
cationic compounds [13], they may affect the membrane
permeability and fluidity, and modify the structural organ-
ization of the lipids surrounding embedded proteins, thus
changing their functional modes [14]. Several studies have
indeed proved that drug–membrane interactions play a key
role in the reversal of MDR [15,16]. Since the development
of a tumour and its therapy are often associated with large
electrolyte disturbances, then the ionic environment within
the cell membrane may be affected, which in turn may
disturb these drug–membrane interactions and hence
decrease the efficiency of the MDR-modulators.
In this study, it was proposed to assess the effects of the
ionic environment on MDR modulator efficiency in terms of
the drug–membrane interactions by testing the ability of the
Ca2 + blocker verapamil, which was selected as the best
known chemosensitizer, to induce dye leakage from uni-
lamellar liposomes at ionic strengths ranging from 0.052 to
0.318 M. In addition, since tumour cells have membranes
with more negative charges than normal eukaryotic cells
[17–19], the effects of the negative electrostatic surface
potential of the membrane were also studied by comparing
the dye leakage induced by verapamil through membranes
containing various amounts of EPA (xEPA= 0, 0.1 and 0.3) at
each I level investigated. The method based on CF leakage
was used here to quantify the interactions between verapa-
mil and the liposome membrane.
2. Materials and methods
2.1. Materials
L-a-Phosphatidylcholine prepared from fresh egg yolk
(EPC), L-a-phosphatidic acid prepared from egg yolk lec-
ithin (EPA), verapamil hydrochloride and Triton X-100
were purchased from Sigma (St. Louis, MO, USA). The
fluorescent dye 4(5)-carboxyfluorescein (dye content:
97.7%) was purchased from Aldrich (Steinheim, Germany),
D-mannitol, from Research Organics Inc. (Cleveland, OH,
USA) and cholesterol, from Fluka (Buchs, Switzerland).
Diethyl ether, Na2SO4, Na2HPO42H2O and NaH2PO4H2O
were purchased from Merck (Darmstadt, Germany), Sepha-
dex PD-10 columns (G-25M), from Pharmacia (Uppsala,
Sweden) and polycarbonate porous membranes, from
Nuclepore Corporation (Pleasanton, CA, USA).
Four external solutions of various I were adjusted to the
same osmolarity with D-mannitol (xe = 360 mosM): 20 mM
phosphate, 290 mM D-mannitol (I = 0.052 M), 20 mM
phosphate, 227 mM D-mannitol, 30 mM Na2SO4 (I = 0.124
M), 20 mM phosphate, 138 mM D-mannitol, 71 mM Na2SO4
(I = 0.204 M), 20 mM phosphate, 136 mMNa2SO4 (I = 0.318
M). All these solutions were adjusted to pH 7.4 at 37 jC.
Internal vesicular solution was 100 mM phosphate, 50 mM
CF, pH 7.4 at 37 jC (xi = 360 mosM). Verapamil hydro-
chloride and Triton X-100 were dissolved in water.
2.2. Liposomes loaded with CF
Large unilamellar vesicles (LUV) composed of EPC/
EPA/cholesterol (9:0:1, 8:1:1, 6:3:1) were prepared by
reverse-phase evaporation, as previously described [20].
The removal of the external CF was carried out by passage
through four Sephadex G-25 columns eluted with the
external solution (20 mM phosphate, 290 mM D-mannitol
(I = 0.052 M)). CF is a hydrophilic probe whose fluores-
cence is self-quenched at concentrations above 10 mM [21].
2.3. Estimation of the ionic strength (I) of the external
solutions
The ionic strength of the external solutions was calcu-
lated according to the following equation:
I ¼ 0:5
X
ðCi  ziÞ ð1Þ
where Ci is the concentration of species i, with valence zi.
Applying the Henderson–Hasselbalch equation to the
sodium phosphate buffer dissociation allowed the calcula-
tion of the ionic concentrations (Ci) in Na
+, H2PO4
 and
HPO4
2 at pH 7.4. The ionization constant (pKa = 6.76 at 37
jC) used in this calculation was estimated from the data
given by Perrin and Dempsey [22], i.e., pKa = 6.80 at 25 jC
and dpKa/dT= 0.0028 u/jC.
As a weak electrolyte, Na2SO4 dissociates in aqueous
solution depending on its concentration. At any given
Na2SO4 concentration (CT), the dissociation degree (aT) is
given by
aT ¼ ðxT=2 CTÞ  0:5 ð2Þ
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where xT, the osmolarity associated with CT, was calculated
from the data given by Wolf et al. [23]. Using these aT
values, then the ionic concentrations (Ci) in Na
+ (CNa+ = 2
CT aT) and SO42 (CSO42  =CT aT) could be estimated
at each Na2SO4 concentration used.
2.4. Kinetic measurements
The kinetics of CF leakage from liposomes were per-
formed using an SFM25 spectrofluorimeter connected to a
32-bit workstation and a software for Windows (Bio-Tek
Kontron Instruments, Milan, Italy) was used. The excitation
wavelength was 484 nm, and the fluorescence emission was
measured at 512 nm (both slit widths at 10 nm).
Loaded liposomes (20 Al) were mixed with external
solution (2 ml, final volume) and equilibrated at 37 jC
using a Hetofrig CB 11E thermostat (Heto, Allerød, Den-
mark). Samples were stirred continuously and the reaction
begun with the addition of 0–1.12 mM verapamil (or 0–8.4
mol verapamil/mol lipid). Total reaction time was 15 min at
which point 50 Al of 10% (w/v) Triton X-100 was added to
disperse the liposomes and allow determination of the total
amount of fluorescence associated with the entrapped dye in
each sample, i.e., 100% total dye leaked. Previous to the
experiments, independent calibrations were performed to
100% relative fluorescence at each I investigated by adding
10% Triton X-100 in a liposome sample, and to 0% relative
fluorescence on bi-distilled water (auto-blank). Results were
plotted as the percentage of total fluorescence observed as a
function of reaction time.
2.5. Data analysis
At each I, xEPA and verapamil concentration, the varia-
tions with time in the fluorescence signal were fitted to the
equation of a two-phase exponential association:
100 ðFt  F0Þ=ðFl  F0Þ ¼ Aa  ð1 ekatÞ þ Ab
 ð1 ekbtÞ ð3Þ
where Ft, Fl and F0 are the relative fluorescence intensity
at time t, timel and zero time, respectively. Aa (%) and Ab
(%) are the normalized amplitude, and ka and kb, the
apparent rate constants (min 1).
The variations in the percentage of total dye leaked with
different drug concentrations were fitted to the following
equation by nonlinear least squares regression:
Total dye leaked ð%Þ ¼ 100 ½Drug	h=ðPDh50 þ ½Drug	hÞ
ð4Þ
where PD50 is the drug dose inducing 50% dye leakage
from the liposomes and h is the Hill coefficient, i.e., the
parameter characterizing the co-operativity of the perme-
ation process.
2.6. Statistical analysis
Data are expressed as meanF S.E. Linear, bilinear and
nonlinear regression lines were calculated using the least-
square method. Values of P < 0.05 were considered signifi-
cant.
3. Results
3.1. Drug permeation properties (PD50 and h) depending
on I and xEPA
The kinetics of CF leakage induced by verapamil through
the membrane of unilamellar liposomes (EPC/EPA/choles-
terol) were quantified for 15 min (37 jC) at I = 0.052, 0.124,
0.204 and 0.318 M, and xEPA= 0, 0.1 and 0.3. This leakage
was induced from the majority of the vesicles since the
observed values of FtF0, as a function of time, increased
gradually until FtF0 =FlF0, i.e., the kinetics of CF
leakage always reached the same equilibrium level of 100%
at tl, regardless of xEPA, I and [verapamil] (Fig. 1). Fig. 2
illustrates the effects of I and xEPA on the extent of the
leakage induced by verapamil from the liposomes at the end
of the incubation period (15 min). In all the sets of experi-
ments, the mole fraction of cholesterol was the same
(xchol = 0.1), as was the sum of those of EPC (xEPC) and
EPA (xEPA), i.e., xEPC + xEPA= 0.9. The PD50 and h values
determined for the dye leakage induced by verapamil after a
3-min period of incubation (initial rate of CF leakage) with
the liposomes are given in Table 1. At each xEPA inves-
Fig. 1. Kinetics of the CF leakage induced by verapamil from liposomes:
the leakage of CF entrapped was induced by (1) 1.12 mM verapamil at
xEPA= 0 and I = 0.318 M ( F0 = 31.0% and Fl= 97.3%), (2) 0.37 mM
verapamil at xEPA= 0.10 and I = 0.052 M ( F0 = 44.6% and Fl= 98.4%),
and (3) 0.26 mM verapamil at xEPA= 0.30 and I = 0.124 M ( F0 = 66.7% and
Fl= 99.4%). The units along the Y axis were determined previous to the
experiments, by performing a calibration to 100% relative fluorescence at
each I investigated by adding 10% Triton X-100 in a liposome sample, and
an auto-blank to 0% relative fluorescence on bi-distilled water. The
variations with time in the fluorescence signal were fitted to Eq. (3).
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tigated, verapamil induced a significant ionic strength-
dependent leakage when added at concentrations ranging
from 0 to 1.12 mM. The overall log(1/PD50) vs. 1/MI linear
regression was highly significant (r2z 0.957; P < 0.0001) at
each xEPA level and the value of the positive slope (dlog(1/
PD50)/d(1/MI)) of this regression increased significantly
with xEPA (r
2 = 0.964; P < 0.001). These results indicate that
the efficiency of verapamil to induce dye leakage from
unilamellar liposomes decreased with increasing I (1/MI
decrease) and that this effect was counteracted by increasing
xEPA, which in turn increased the negative surface potential
(W) of the membranes. With the ratio between the mem-
brane volume and the external solution volume, which was
estimated to be equal to 0.0001 in a sample, and the octanol-
buffer distribution calculated by Castaing et al. [24] for
verapamil (logD = 2.26 at pH 7.4), the verapamil concen-
trations in the membranes per mol lipid were calculated. At
the PD50 of verapamil, these lipid/drug molar ratios ranged
from 1:0.02 (I = 0.052 M at xEPA= 0.3) to 1:0.24 (I = 0.318 M
at xEPA= 0).
The membrane permeation induced by verapamil was a
co-operative process (1.3 < h < 3.5), characterized by a Hill
coefficient (h) increasing with I and xEPA (Table 1). What-
ever xEPA, the overall logh vs. 1/MI linear regression was
statistically significant (r2z 0.708; PV 0.01). However,
there was no significant correlation between the negative
slope value dlogh/d(1/MI) of these regressions and xEPA.
This result suggests that the binding of one verapamil
molecule to the membrane somehow accelerated the binding
of the subsequent molecules to a greater extent at low than
at high 1/MI. An alternative interpretation is that the number
of verapamil molecules concomitantly interacting at the
same site on the membrane and inducing a sufficiently
strong destabilization of the bilayer for dye leakage to occur
may be higher at low than at high 1/MI. Since the xEPA
variations did not significantly affect the slope of the logh
vs. 1/MI linear regressions, then it is possible that in the 0 to
0.3 xEPA range investigated here, the changes in the negative
surface potential (W) of the membranes did not significantly
Table 1
Effects of xEPA and I on the permeation dose (PD50) and Hill coefficient (h)
of verapamil
xEPA I (M) PD50 (mM) h
0.0 0.052 0.94F 0.08 1.27F 0.13
0.0 0.124 1.34F 0.05 1.48F 0.12
0.0 0.204 1.56F 0.08 1.88F 0.16
0.0 0.318 1.77F 0.02 2.15F 0.08
0.1 0.052 0.49F 0.03 1.81F 0.06
0.1 0.124 0.74F 0.03 1.99F 0.08
0.1 0.204 0.98F 0.03 2.28F 0.01
0.1 0.318 1.16F 0.09 2.56F 0.15
0.3 0.052 0.16F 0.01 2.41F 0.05
0.3 0.124 0.30F 0.01 2.47F 0.00
0.3 0.204 0.42F 0.01 2.98F 0.05
0.3 0.318 0.55F 0.01 3.54F 0.05
The leakage of CF entrapped was induced by 0 to 1.12 mM verapamil (or 0
to 0.15 mol verapamil in the membrane/mol lipid) through LUV
membranes. The leakage was quantified following a 3-min incubation
period (initial rate of CF leakage) at 37 jC (pH 7.4). The permeation
parameters (PD50 and h) were determined according to Eq. (4). The
parameters PD50 and h are expressed as meanF S.E. of the permeation
parameters obtained from the study of two LUV preparations.
Fig. 2. Effects of I and xEPA on the extent of CF leakage induced by
verapamil from liposomes after a 15-min period of incubation: the leakage
of CF entrapped was induced by 0 to 1.12 mM verpamil (or 0 to 0.15 mol
verapamil in the membrane/mol lipid) through LUV membranes at
I = 0.052, 0.124, 0.204 and 0.318 M, and xEPA= 0, 0.1 and 0.3. The extent
of CF leakage was quantified after a 15-min period of incubation at 37 jC
(pH 7.4) and the total amount of fluorescence associated with the entrapped
dye in each sample, i.e., 100% total dye leaked, was determined by
dispersing the liposomes with 10% Triton X-100. Previous to the
experiments, independent calibrations were performed to 100% relative
fluorescence at each I investigated by adding 10% Triton X-100 in a
liposome sample, and to 0% relative fluorescence on bi-distilled water
(auto-blank). Each point is the result obtained from the study of one LUV
preparation.
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modify the ionic strength-dependence of the co-operativity
(h) of the dye leakage induced by verapamil.
3.2. Multiple correlation between the permeation dose
(PD50) of verapamil, 1/
p
I and xEPA
The results presented above clearly indicate that CF
leakage through membranes was prevented by a decrease
of the absolute value of the negative surface potential
realised either by increasing I or decreasing xEPA.
Multiple correlation analysis was therefore performed
between the efficiency (log(1/PD50) of verapamil, 1/MI,
and xEPA. The results can be expressed by the following
equation:
logð1=PD50Þ ¼ 0:15ðF0:01Þ  1=MI þ 2:07ðF0:08Þ
 xEPA þ 2:46ðF0:03Þ ð5Þ
This bilinear dependence of log(1/PD50) on 1/MI and xEPA
(F(2,21) = 420.0, sresidual = 0.050, r= 0.988 and P < 0.000001)
was highly significant. Nearly 98% of the efficiency of
verapamil to induce dye leakage could be explained here
in terms of 1/MI and xEPA (r
2 = 0.976).
Fig. 3 shows the multiple correlation observed between
log(1/PD50), 1/MI and xEPA. It clearly illustrates the fact
that the higher the 1/MI and xEPA, the higher the ability of
verapamil to induce dye leakage through membranes,
whereas the lower the 1/MI and xEPA, the lower the ability
of verapamil to induce dye leakage through membranes.
3.3. Multiple correlation between the apparent rate cons-
tants ka and kb of the dye leakage, 1/
p
I and the verapamil
concentration (C)
The induction of dye leakage through bilayer membranes
by a drug can be expected to involve two stages: the
interaction between the drug and its receptors at the mem-
brane interface (first stage) and the interaction between the
drug and the phospholipids in the core of the membrane
(second stage) [20]. In the present study, the kinetics of CF
leakage was fitted to the equation of a two-phase exponen-
tial association model. The apparent rate constants ka and kb
of the leakage process were determined at each C, I and xEPA
investigated. The values of ka (slow kinetic step) ranged
between 0.011 and 0.063 min 1 (relaxation time sa = 16–91
min), and those of kb (fast kinetic step) between 0.10 and
0.50 min 1 (relaxation time sb = 2–10 min).
Fig. 3. Bilinear dependence of the permeation ability (log(1/PD50)) of verapamil on 1/MI and xEPA: the leakage of CF entrapped was induced by 0 to 1.12 mM
verapamil (or 0 to 0.15 mol verapamil in the membrane/mol lipid) through LUV membranes. The leakage was quantified following a 3-min period of
incubation (initial rate of CF leakage) at 37 jC (pH 7.4) at I = 0.052, 0.124, 0.204 and 0.318 M, and xEPA= 0, 0.1 and 0.3. The permeation parameters (PD50 and
h) were determined according to Eq. (4). Each point is the result obtained from the study of one LUV preparation. The experimental data above (filled circles)
and below (open circles) the plane of the multiple regression are plotted on the figure.
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The respective effects of C and I on these apparent rate
constants were then quantified at each EPA level investigated
by performing multiple correlation analysis between logk, C
and 1/MI. The values of the dlogk/dC and dlogk/d(1/MI)
regression coefficients obtained are given in Table 2.
Regardless of xEPA, there was a significant bilinear depend-
ence of logka on C and 1/MI (r
2z 0.680; P < 0.001) (Table
2). Also, the dlogka/dC regression coefficient had a positive
value which was 3.7–3.8 times higher at xEPA= 0.3 than at
xEPA= 0–0.1, whereas the dlogka/d(1/MI) regression coeffi-
cients had positive values which increased with xEPA. These
results indicate that the slow kinetic step in the leakage
process (logka) depended on C and 1/MI, and that these
relationships were strengthened at xEPA= 0.3. It is therefore
likely that this slow kinetic step was driven by the electro-
static interactions occurring between the cationic verapamil
and the phospholipid head groups at the lipid/buffer inter-
face. The data given in Table 2 also show that the bilinear
dependence of logkb on C and 1/MI was not significant at
xEPA= 0, whereas it was significant at xEPA= 0.1 and 0.3
(r2z 0.435; PV 0.01). In addition, the value of the dlogkb/
dC regression coefficient was positive and increased with
xEPA, whereas that of the dlogkb/d(1/MI) regression coeffi-
cient did not differ significantly from zero at any of the xEPA
levels investigated. These results indicate that the fast kinetic
step in the dye leakage process (logkb) depended on C, and
that this effect was strengthened by increasing xEPA, whereas
this step did not depend on 1/MI. It therefore seems quite
likely that this fast kinetic step may have been driven by the
hydrophobic interactions occurring between verapamil and
the acyl chains of the phospholipids in the lipophilic core of
the membrane.
4. Discussion
The Ca2 + blocker verapamil was the first compound
found to reverse MDR in tumour cells [8]. The relevant
aspects of its chemical structure are two planar aromatic
rings and a basic nitrogen atom. In the present study, the
ability of verapamil to induce the CF leakage from lip-
osomes was quantified at various I and xEPA levels. The
kinetic approach used here to study the leakage process
brought to light several aspects of the interactions between
verapamil and the membranes.
At any given I and xEPA investigated in the present study,
verapamil induced 50% dye leakage within 15 min in the
80–820 AM range (Fig. 2). Verapamil has been previously
found to be less efficient on PC/PS/PE (3:4:3) liposomes at
I = 0.170 M [15] and on soybean lipids/PS/cholesterol
(f 5.7:1.4:2.9) liposomes at I = 0.017 M [16]. Bramhall et
al. [25] have suggested, however, that the rate of CF leakage
may depend on the nature of the base used to adjust the
intravesicular pH. This may well explain why verapamil
was found here to be more efficient than previous works
reported it to be [15,16].
The results of the present study show the existence of a
highly significant bilinear dependence of the efficiency
(log(1/PD50)) of verapamil on the increase in xEPA and 1/
MI. Ionization of the phospholipid head groups at the
membrane interface generates an electrostatic surface
potential W, which in turn brings about a redistribution
of the protons, cations and anions in the vicinity of the
interface [26]. In the present study, increasing xEPA fav-
oured electrostatic interactions between the cationic vera-
pamil and the anionic phosphate groups, both directly via
the increase in the negative surface charge density (r) and
indirectly via the decrease in the interfacial pH and the
increase in the interfacial pK of the drug. This indirect
effect increased further the electric charge of verapamil.
All in all, the dependence of the CF leakage observed here
on xEPA is in agreement with the data published by Majee
and Chakabarti [27]. Our results are also in line with the
findings obtained by Kra¨mer et al. [28] showing that the
liposome/buffer distribution of cationic drugs increases
with the mole fraction of anionic lipids. As the ionic
strength was increased, small ions in the external solution
screened the electric charge of verapamil and that of the
ionized groups of the membrane [29]. The electrostatic
interactions therefore decreased due to the decrease in both
the apparent electric charge of the drug and the surface
potential (W) of the membrane. According to the linearised
Gouy–Chapman theory, the surface potential (W) is pro-
portional to the surface charge density (r) and to 1/MI
[26,29,30]. Consequently, the ability of verapamil (log(1/
PD50)) to induce dye leakage through membranes was
favoured by the enhanced electrostatic interactions occur-
ring at high xEPA and 1/MI levels, and reduced by the
decrease in these interactions occurring at low xEPA and
1/MI levels.
Table 2
Bilinear dependence of the apparent rate constants ka and kb on 1/MI and C
k xEPA dlogk/dC
(mM 1)
dlogk/d
(1/MI) (M1/2)
y-intercept r2 P
ka 0.0 1.08F 0.08 0.184F 0.021  2.63F 0.10 0.825 < 0.001
0.1 1.06F 0.13 0.197F 0.029  2.51F 0.13 0.680 < 0.001
0.3 3.97F 0.33 0.307F 0.034  3.29F 0.15 0.820 < 0.001
kb 0.0 0.09F 0.08  0.014F 0.023  0.46F 0.11 0.171 NS
0.1 0.52F 0.12 0.001F 0.032  0.81F 0.13 0.516 < 0.001
0.3 0.80F 0.55  0.081F 0.063  0.51F 0.28 0.435 < 0.01
The leakage of CF entrapped was induced by 0 to 1.12 mM verapamil (or 0
to 0.15 mol verapamil in the membrane/mol lipid) through LUV
membranes. The kinetics of dye leakage induced by verapamil at 37 jC
(pH 7.4) were recorded during 15 min and the total amount of fluorescence
associated with the entrapped dye in each sample, i.e., 100% total dye
leaked, was determined by dispersing the liposomes with 10% Triton X-
100. Prior to the experiments, independent calibrations were performed to
100% relative fluorescence at each ionic strength investigated by adding
10% Triton X-100 in a liposome sample, and to 0% relative fluorescence on
bi-distilled water (auto-blank). The apparent rate constants (in min 1) were
determined according to Eq. (3). MeansF S.E. were determined by the
simultaneous fitting of the data obtained from two LUV preparations. The
determination coefficient (r2) and p-level ( P) of the regressions are also
given.
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The kinetics of the CF leakage process induced here by
verapamil can be fairly described by a two-step process.
The rate constant of the slow kinetic step (ka) was eight to
nine times smaller than that of the fast kinetic step (kb).
Since no kinetic model describing this leakage seems to
be available in the literature, the rate constants ka and kb
determined here were apparent ones. Multiple correlation
analysis showed that both logka and logkb depended on C,
whereas only logka depended on 1/MI. Since ka depended
on 1/MI whereas kb did not, it is possible that ka might be
ascribed to the first kinetic step in the leakage process (ka
apparent = k1 apparent), whereas kb might be ascribed to
the second kinetic step (kb apparent = k2 apparent). How-
ever, further studies are required to confirm this statement.
The slow kinetic step (ka) driven by electrostatic inter-
actions varied with C and the dlogka/dC coefficient value
was nearly four times higher at xEPA= 0.3 than at xEPA= 0
and 0.1 (Table 2). This effect might be due to the ability
of verapamil to accumulate in the regions of the mem-
brane where EPA molecules predominate. At xEPA= 0.3, it
may then have reached the critical concentration on the
membrane which is required to induce dye leakage in a
co-operative manner at rather low concentrations. When
xEPA was low, verapamil might have dispersed more
widely over the membrane and reached this critical con-
centration on the lipid at much higher concentrations [31].
The fast kinetic step (kb) driven by hydrophobic interac-
tions was also found to vary with C, depending on xEPA.
In fact, the dlogkb/dC coefficient value was nine times
higher at xEPA= 0.3 than at xEPA= 0 (Table 2). This result
suggests that at high EPA levels, the strong electrostatic
repulsions occurring between the anionic phospholipid
head groups at the membrane/buffer interface may have
induced bilayer destabilization more deeply into the core
of the membrane. Therefore, the efficiency of verapamil to
increase further this destabilization favouring the occur-
rence of dye leakage was higher at xEPA= 0.3 than at
xEPA= 0 and 0.1.
To sum up, the overall outcome of the molecular events
described above seems to be that the ability of verapamil
(log(1/PD50)) to induce dye leakage was favoured by the
enhanced electrostatic interactions occurring at high xEPA
and 1/MI levels, and reduced by the decrease in these
interactions occurring at low xEPA and 1/MI levels. Con-
comitantly, the efficiency of verapamil was increased by
the enhanced hydrophobic interactions occurring at high
xEPA levels, and decreased by the weakening of these
interactions occurring at low xEPA levels. The results of
the present study point to the importance of parameters such
as the ionic strength and the membrane surface potential,
which should be taken into account by authors using the
method based on CF leakage to quantify the efficiency of
drugs.
It was concluded from the results of this study that when
the negative surface potential of the membranes is high, as
occurs in tumour cells [17–19], the MDR reversal induced
by verapamil might be enhanced by favourable drug–
membrane interactions in patients with severe hypo-electro-
lytic (Na+ and K+) disorders, whereas the MDR reversal
might be reduced by unfavourable drug–membrane inter-
actions in patients with severe hyper-electrolytic (Ca2 +, Na+
and K+) disorders.
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